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Abstract
Introduction: AMP-activated protein kinase (AMPK) maintains cultured chondrocyte matrix homeostasis in
response to inflammatory cytokines. AMPK activity is decreased in human knee osteoarthritis (OA) chondrocytes.
Liver kinase B1 (LKB1) is one of the upstream activators of AMPK. Hence, we examined the relationship between
LKB1 and AMPK activity in OA and aging cartilages, and in chondrocytes subjected to inflammatory cytokine
treatment and biomechanical compression injury, and performed translational studies of AMPK pharmacologic
activation.
Methods: We assessed activity (phosphorylation) of LKB1 and AMPKa in mouse knee OA cartilage, in aging mouse
cartilage (6 to 24 months), and in chondrocytes after mechanical injury by dynamic compression, via
immunohistochemistry or western blot. We knocked down LKB1 by siRNA transfection. Nitric oxide, matrix
metalloproteinase (MMP)-3, and MMP-13 release were measured by Griess reaction and ELISA, respectively.
Results: Knockdown of LKB1 attenuated chondrocyte AMPK activity, and increased nitric oxide, MMP-3 and MMP-
13 release (P <0.05) in response to IL-1b and TNFa. Both LKB1 and AMPK activity were decreased in mouse knee
OA and aged knee cartilage, and in bovine chondrocytes after biomechanical injury. Pretreatment of bovine
chondrocytes with AMPK activators AICAR and A-769662 inhibited both AMPKa dephosphorylation and catabolic
responses after biomechanical injury.
Conclusion: LKB1 is required for chondrocyte AMPK activity, thereby inhibiting matrix catabolic responses to
inflammatory cytokines. Concurrent loss of LKB1 and AMPK activity in articular chondrocytes is associated with OA,
aging and biomechanical injury. Conversely, pharmacologic AMPK activation attenuates catabolic responses to
biomechanical injury, suggesting a potentially novel approach to inhibit OA development and progression.
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Introduction
Osteoarthritis (OA) is a disorder of the synovial joint,
which culminates in articular cartilage degeneration, and
associated pain and disability [1,2]. Age and biomechanical
injury are implicated as primary risk factors for OA [1,2].
Chondrocytes, the sole cells residing within articular
cartilage, are responsible for maintaining the homeostatic
balance between matrix anabolism and catabolism [1,2].
However, biomechanical injury initiates a sequence of
biological events in the joint, in which chondrocyte dys-
function and loss of viability lead to progressive articular
cartilage damage [3]. In addition, aged chondrocytes exhi-
bit an impaired ability to respond to mechanical and
inflammatory insults, manifested as decreased anabolic
activity and an increase in catabolic activity, thereby com-
promising cartilage extracellular matrix integrity [4,5].
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IL-1b, TNFa, and other inflammatory mediators in
injured and aging joints [6-9] play a significant role in
promoting catabolism of type II collagen and proteogly-
cans [2]. The serine/threonine protein kinase AMP-acti-
vated protein kinase (AMPK), a fuel-sensing, master
regulator of energy homeostasis and cellular metabolism
[10,11], exerts anti-inflammatory effects, partly mediated
by inhibition of NF-B signaling [12]. We demonstrated
that AMPK activity is constitutively present in normal
articular chondrocytes, but is decreased in human knee
OA chondrocytes [13]. IL-1b and TNFa induce marked
loss of AMPK activity in normal articular chondrocytes
[13]. Conversely, AMPK pharmacological activators
attenuate cartilage explant and monolayer cultured chon-
drocyte procatabolic responses to IL-1b and TNFa [13].
Hence, decreased AMPK activity in articular chondro-
cytes has the potential to disrupt cartilage homeostasis by
promoting matrix catabolism, thereby contributing to
progression of OA.
AMPK activation is induced by several upstream kinases
via AMPKa subunit phosphorylation at a conserved threo-
nine; dephosphorylation by protein phosphatases inacti-
vates AMPK [10,11]. Liver kinase B1 (LKB1), a serine/
threonine protein kinase that was first identified as a
tumor suppressor, is one of the upstream kinases that acti-
vate AMPK [10,11]. Here, we determined the relationship
between LKB1 and AMPK activities in cultured chondro-
cytes, and examined phosphorylation of LKB1 and
AMPKa in human knee OA chondrocytes, in mouse knee
OA and aging cartilages, and in bovine knee chondrocytes
embedded in alginate after biomechanical injury. Our
results closely link matrix catabolism with decreased LKB1
and AMPK activities, present in OA, aging, and injured
chondrocytes. Conversely, we establish that AMPK phar-
macologic activators inhibit catabolic responses following
biomechanical injury in chondrocytes.
Materials and methods
Reagents
All chemical reagents were obtained from Sigma-Aldrich
(St Louis, MO, USA), unless otherwise indicated. AMPK
pharmacologic activators 5-aminoimidazole-4-carboxya-
mide ribonucleoside (AICAR) and A-769662 were from
Tocris Bioscience (Bristol, UK). Recombinant human IL-
1b and TNFa, and matrix metalloproteinase (MMP)-3
and MMP-13 ELISA kits were purchased from R&D
Systems, Inc. (Minneapolis, MN, USA). Antibodies to
phospho-LKB1 (Ser428), phospho-AMPKa (Thr172),
total AMPKa and cleaved caspase-3 were from Cell Sig-
naling Technology, Inc. (Danvers, MA, USA) for western
blot, and from Abcam (Cambridge, MA, USA) for
immunohistochemistry. Human LKB1 siRNA and con-
trol siRNA were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA).
Studies of human knee articular chondrocytes
Studies were performed in compliance with an institu-
tionally reviewed and approved human subject protocol
by the IRB at the Scripps Research Institute (La Jolla,
CA, USA). The human knee chondrocytes were isolated
from autopsy donors (no consent was needed) that were
graded macroscopically according to a modified Outer-
bridge scale [14,15]. Grade I represents intact cartilage
surface (normal); grade II represents minimal fibrillation
(OA); and grade III represents overt fibrillation (OA)
[14,15]. Human chondrocytes were cultured in high-glu-
cose DMEM with 10% FCS, 100 μg/ml streptomycin,
and 100 IU/ml penicillin at 37°C, and no later than first
passage chondrocytes were used for all experiments.
Unless otherwise indicated, chondrocytes were plated at
2.5 × 105 cells per well in 250 μl medium on the day
before the experimental treatment in 12-well plates.
Experimental osteoarthritis models in mice
All mouse experiments were performed in compliance
with an institutionally reviewed and approved protocol by
IACUC at the Scripps Research Institute. Joint instability-
induced OA was induced in 2-month-old C57BL/6J mice
by transection of the anteromedial meniscotibial ligament
and the medial collateral ligament, and animals were
euthanized 8 weeks later. Aging C57BL/6 mice were kept
under normal conditions and knee joints were compared
at 6, 12 and 24 months of age. Knee joints from surgical
OA and aging mice groups were resected, fixed in 10%
zinc-buffered formalin (Z-Fix; Anatech, Battle Creek, MI,
USA) for 2 days, decalcified in TBD-2 (Shandon, Pitts-
burgh, PA, USA) for 72 hours, and paraffin embedded
using standard protocols.
Immunohistochemistry
Mouse knee cartilage sections were pretreated with hya-
luronidase (2 mg/ml) for 1 hour before being treated
with 3% (vol/vol) H2O2 for 10 minutes. The sections
were then blocked with 10% goat serum for 2 hours at
room temperature. After washing with Tris-buffered sal-
ine, rabbit antibodies to phospho-LKB1 (Ser428; 1:50
dilution), phospho-AMPKa (Thr172; 1:50 dilution) and
the negative control rabbit IgG (1 μg/ml) were applied to
the sections and incubated overnight at 4°C. Next, the
sections were washed with Tris-buffered saline, incubated
with biotinylated goat anti-rabbit IgG secondary antibody
for 30 minutes, and then incubated for 30 minutes using
the Histostain Plus kit (Invitrogen, Carlsbad, CA, USA).
Finally, the sections were washed and incubated with
3,3’-diaminobenzidine substrate for 2 to 5 minutes.
Quantification of positive staining chondrocytes
Positive staining cells in the noncalcified region of
femoral and tibial cartilage of each mouse knee section
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were counted from six different areas of the knee
(representing the center of the femoral condyle and tibia
that are not covered by the menisci as well as the med-
ial and lateral femoral condyles and tibia) adapted from
the previous method [16]. The cellularity was quantified
by counting the number of cells stained with hematoxy-
lin on corresponding, adjacent sections. The number of
positive cells for each antibody was expressed as the
percentage of positive staining cells via immunohisto-
chemistry, relative to the number of cells stained with
hematoxylin in corresponding sections.
Knockdown of LKB1 in human knee articular
chondrocytes
Normal cultured primary human knee articular chon-
drocytes (passage 1) were transfected with siRNAs of
LKB1 and nontarget control. Transfection used the
Amaxa Nucleofection™ system (Amaxa Inc., Gaithers-
burg, MD, USA), according to the manufacturer’s proto-
col. Knockdown of expression of LKB1 was examined
by SDS-PAGE/western blot analysis.
Bovine knee chondrocytes subjected to biomechanical
injury
Bovine articular chondrocytes, isolated from mature cow
knees as described previously [17], were embedded in 2%
alginate discs with 6 mm diameter and 3 mm height. The
chondrocyte-alginate constructs were then cultured in
DMEM medium, containing 10% FBS and 1% penicillin-
streptomycin, in a 37°C, 5% CO2 incubator for 3 to 4
weeks. This time period was based on prior knowledge
that chondrocytes embedded in alginate require approxi-
mately 3 weeks to establish a consistent pericellular and
territorial extracellular matrix [18]. This approach
allowed for robust extracellular matrix production before
application of biomechanical injury, which used a cus-
tom-made mechanical compression apparatus housed
inside a 37°C, 5% CO2 incubator. Sub-lethal injury was
optimized to induce no significant increase cell death at a
time point immediately after completion of compression
(relative to no compression), with cell viability deter-
mined in situ by the Live/Dead cell viability assay (Invi-
trogen). The sub-lethal injury condition (defined as no
immediate cell death), was associated with delayed cell
death (to about 25% of cells) after injury. The conditions
involved continuous dynamic unconfined compression at
24% strain, with 12% amplitude at 0.5 Hz for 16 hours.
The alginate-chondrocyte constructs were then cultured
and analyzed at 0, 1, 2 and 5 days after injury. Chondro-
cytes were isolated from the constructs by dissolution of
alginate using a 50 mM ethylenediamine tetraacetic acid/
PBS solution, and the cell lysates were subjected to SDS-
PAGE/western blot analysis for expression of cleaved cas-
pase-3, an apoptosis marker, and phosphorylation of
LKB1 and AMPKa. Conditioned media were also col-
lected for measurement of release of nitric oxide (NO)
and glycosaminoglycans (GAGs) [13]. Expression of
MMP-3 was determined at both the mRNA level by
quantitative RT-PCR analysis and the protein level by
SDS-PAGE/western blot analysis of the conditioned
media.
Statistical analyses
All data were uniformly expressed as the mean ± stan-
dard deviation. Statistical analyses were performed by
two-way analysis of variance with Bonferroni post-hoc
test using GraphPad PRISM 5 (GraphPad, La Jolla, CA,
USA). P <0.05 was considered significant.
Results
Inhibition of phosphorylation of AMPKa and enhanced
catabolic responses to IL-1b and TNFa via LKB1
knockdown in chondrocytes
To determine whether LKB1 regulates AMPK activity in
chondrocytes, we knocked down LKB1 expression in
normal cultured human knee articular chondrocytes (pas-
sage 1) via transfection with siRNAs of LKB1 and the non-
target control. The significant decrease in LKB1 protein
expression by siRNA was confirmed by western blot
(Figure 1A). Next, we examined phosphorylation of
AMPKa in the LKB1 knockdown chondrocytes and in the
control cells in the presence or absence of IL-1b and
TNFa. As with our previous observation [13], phosphory-
lation of AMPKa was constitutively present but
was decreased by IL-1b and TNFa in the control cells
(Figure 1B). In comparison, phosphorylation of AMPKa
was almost completely inhibited at the basal level and was
blunted by IL-1b and TNFa in the LKB1 knockdown
chondrocytes (Figure 1B), indicative of a necessary regula-
tory role of LKB1 for AMPK activation in chondrocytes.
In these experiments, we saw increased NO release by
82% and 115% in response to IL-1b and TNFa, respec-
tively, compared with control cells (Figure 1C). In addi-
tion, release of MMP-3 and MMP-13 in response to IL-1b
and TNFa were also enhanced in LKB1 knockdown chon-
drocytes (Figure 1D,E). Conversely, overexpression of
LKB1 in chondrocytes via transfection prevented depho-
sphorylation of AMPKa and inhibited NO production and
MMP-3 and MMP-13 release in response to IL-1b and
TNFa (data not shown).
Loss of phosphorylation of LKB1 and AMPKa in cultured
human knee osteoarthritic chondrocytes
Since decreased phosphorylation of AMPKa was pre-
viously observed in human knee OA chondrocytes [13],
we tested here for concurrent decrease of chondrocyte
LKB1 and AMPKa phosphorylation. Cultured primary
human chondrocytes (passage 1) with a range of normal
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Figure 1 Knockdown of LKB1 in articular chondrocytes attenuates AMPK activity and promotes matrix catabolic responses. Human
primary normal knee articular chondrocytes were transfected with liver kinase B1 (LKB1) and control siRNA. Two days after transfection, cells
were either (A) used directly for western blot analysis of LKB1 expression or (B) treated with IL-1b (10 ng/ml) and TNFa (10 ng/ml) for 18 hours
followed by western blot analysis for phosphorylation of AMP-activated protein kinase alpha (AMPKa) and total AMPKa. (C) Nitric oxide (NO)
release, (D) matrix metalloproteinase (MMP)-3 release and (E) MMP-13 release were then analyzed from the conditioned media by Griess
reaction and ELISA, respectively. Data representative of three individual experiments. *P <0.001, **P <0.01, #P <0.05 relative to the control (Ctrl).
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(grade I), mild OA (grade II) and OA (grade III) were
subjected to SDS-PAGE/western blot analysis of phos-
phorylation of LKB1 and AMPKa. Phosphorylation of
LKB1 was constitutively present in grade I and grade II
chondrocytes, but was substantially decreased in grade
III chondrocytes (Figure 2), where there was decrease in
AMPK phosphorylation (Figure 2).
Concomitant reduction of phosphorylation of LKB1 and
AMPKa in mouse knee osteoarthritic and aged mouse
knee cartilages in situ
Immunohistochemistry analysis of mouse knee sections of
surgically induced OA and sham control (with Osteoar-
thritis Research Society International scores of 5 and 0,
respectively) revealed that phosphorylated LKB1 and
AMPKa were concomitantly decreased in mouse OA
knee cartilage, compared with the sham control (Figure 3).
Additionally, immunohistochemistry analysis of mouse
knee sections 6, 12 and 24 months old (with Osteoarthritis
Research Society International scores of 0.5, 1 and 1,
respectively) revealed that the numbers of cells staining
positively for either phosphorylated LKB1 and AMPKa
were similar in 6-month-old and 12-month-old mouse
knee cartilages, but were concomitantly decreased in
24-month-old mice knee cartilages (Figure 4).
Decreased phosphorylation of LKB1 and AMPKa and
increased apoptosis and catabolic responses in
chondrocytes after biomechanical injury in vitro
We cultured normal bovine knee chondrocytes embedded
in 2% alginate (three-dimensional) for 3 to 4 weeks to
allow extracellular matrix production [18] before subject-
ing them to sub-lethal injury by continuous dynamic
unconfined compression at 24% strain, 12% amplitude,
0.5 Hz for 16 hours as described in Materials and
methods. The chondrocyte-alginate constructs were then
cultured and collected at 0, 1, 2 and 5 days after injury. As
seen in Figure 5A, activation of caspase-3, an apoptosis
mediator, became detectable in chondrocytes at 1, 2 and
5 days after compression. In contrast, phosphorylation of
LKB1 and AMPKa started to decrease at 1 day and
became attenuated at 5 days post injury (Figure 5A).
Significant induction of NO release was seen immedi-
ately after injury and leveled off at 2 days post injury
(Figure 5B). Similar results were observed for GAG
release (Figure 5C) that could reflect matrix catabo-
lism. Induction of MMP-3 expression was seen at both
mRNA and protein levels, with the highest level at
2 days after compression (Figure 5D,E). Taken together,
decreased concurrent phosphorylation of LKB1 and
AMPKa were associated with increased proapoptotic
and catabolic responses in chondrocytes following
mechanical injury.
Suppression of increased catabolic responses to injury by
AMPK pharmacologic activators in cultured chondrocytes
Bovine knee chondrocytes embedded in alginate, which
had first been cultured for 3 to 4 weeks, were pretreated
with AMPK pharmacologic activators AICAR (1 mM) and
A-769662 (0.5 mM) for 24 hours before being subjected to
biomechanical injury. After culture for 2 days post injury,
the chondrocyte-alginate constructs and the conditioned
media were collected for analysis of catabolic responses.
As shown in Figure 6, both AICAR and A-769662 pre-
vented dephosphorylation of AMPKa (Figure 6A) and
inhibited caspase-3 activation (Figure 6B) after mechanical
p-LKB1 
-actin 
I I/II II III III III Donor grade 
p-AMPK
AMPK
Figure 2 Loss of phosphorylation of both LKB1 and AMPKa in human knee osteoarthritic chondrocytes. Lysates of cultured primary
human knee chondrocytes (grade I to III) were subjected to western blot analysis with antibodies to phospho-liver kinase B1 (p-LKB1; Ser428)
and phospho-AMP-activated protein kinase alpha (p-AMPKa; Thr172), as described in Materials and methods. Data representative of three
individual experiments (total of 15 different donors).
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Figure 3 Concomitant reduction of phosphorylation of LKB1 and AMPKa in mouse knee osteoarthritic cartilages. Mouse knee sections
from surgical instability-induced osteoarthritis (OA) and the sham control at 8 weeks post surgery were analyzed for phosphorylation of liver
kinase B1 (LKB1) and AMP-activated protein kinase alpha (AMPKa) by immunohistochemistry as described in Materials and methods. Cellularity of
each section was confirmed with hematoxylin staining. Only the cells present in the noncalcified region of femoral and tibial cartilage were
subjected to analysis. Cells staining positively for LKB1 and AMPKa were presented as percentage of cells stained for hematoxylin. Data
representative of two individual experiments (n = 3 animals). *P <0.05 relative to the sham control.
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Figure 4 Concomitant reduction of phosphorylation of LKB1 and AMPKa in aged mouse knee cartilages. Knee sections of mice 6, 12
and 24 months old were analyzed for phosphorylation of liver kinase B1 (LKB1) and AMP-activated protein kinase alpha (AMPKa) by
immunohistochemistry, as described in Materials and methods. Cellularity of each section was confirmed with hematoxylin staining. Only the
cells present in the noncalcified region of femoral and tibial cartilage were subjected to analysis. Cells staining positively for LKB1 and AMPKa
were presented as percentage relative to cells stained for hematoxylin. Data representative of two individual experiments (n = 4 for each time
point). *P <0.01, #P <0.05 relative to the 6-month-old mouse knee cartilage.
Petursson et al. Arthritis Research & Therapy 2013, 15:R77
http://arthritis-research.com/content/15/4/R77
Page 7 of 11
B. C. 








































0 1 2 5 0 1 2 5 
p-LKB1







































Figure 5 Decreased LKB1 and AMPKa phosphorylation and increased apoptosis and catabolic responses after biomechanical injury.
Loss of phosphorylation of liver kinase B1 (LKB1) and AMP-activated protein kinase alpha (AMPKa), in addition to increased caspase-3 activation,
nitric oxide (NO) release, and catabolic activities in bovine chondrocytes after biomechanical injury. Bovine knee articular chondrocytes were
embedded in alginate disks and cultured for 3 to 4 weeks, followed by the sub-lethal biomechanical injury condition described in Materials and
methods. The chondrocyte-alginate constructs were collected at 0, 1, 2 and 5 days after injury. (A) Chondrocytes from both injured and control
groups were then released by dissolution of alginate, and subjected to western blot analysis for expression of cleaved caspase-3,
phosphorylation of LKB1 and AMPKa, and total AMPKa. Conditioned media were employed for analysis of (B) NO and (C) glucosaminoglycan
(GAG) release by Griess reaction and DMMB assay, respectively, and (E) matrix metalloproteinase (MMP)-3 release by western blot analysis.
(D) MMP-3 mRNA expression was also examined by quantitative RT-PCR. Data representative of three individual experiments (n = 3 replicates for
each condition). **P <0.001, *P <0.01, #P <0.05 relative to the control.
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Figure 6 AMPK pharmacologic activators inhibit catabolic responses of chondrocytes to biomechanical injury. Bovine chondrocyte-
alginate disks were pretreated with 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR; 1 mM) and A-769662 (0.5 mM) for 24 hours, and
then subjected to mechanical injury as described in Materials and methods. After culturing for 2 days, the chondrocytes released from alginate
and the conditioned media were used for analysis of (A) phosphorylation of AMP-activated protein kinase alpha (AMPKa) and total AMPKa,
(B) cleaved caspase-3, (C) nitric oxide release and (D) glucosaminoglycan (GAG) release, and (E, F) matrix metalloproteinase (MMP)-3 expression.
Data representative of two individual experiments (n = 3 replicates for each condition). *P <0.01 relative to the control.
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injury. In parallel, both AICAR and A-769662 dramatically
inhibited NO and GAG release and MMP-3 expression at
both mRNA and protein levels after mechanical injury
(Figure 6C,D,E,F).
Discussion
This study demonstrated that activation of AMPK
requires LKB1 in chondrocytes. Knockdown of LKB1
expression via siRNA resulted in attenuation of basal
phosphorylation of AMPKa, as well as significant
enhancement of catabolic responses to IL-1b and TNFa
in chondrocytes. Conversely, overexpression of LKB1 in
chondrocytes via transfection prevented dephosphoryla-
tion of AMPKa and inhibited NO production and
MMP-3 and MMP-13 release in response to IL-1b and
TNFa (data not shown). We observed concomitant loss
of phosphorylation of LKB1 and AMPKa in human
knee OA chondrocytes (grade III) and in mouse knee
OA cartilages.
Aging is a major risk factor for development of OA
[1-4]. Decreased AMPK activation is linked with several
age-associated diseases [19]. For example, deficiency of
AMPK exacerbates aging-induced myocardial dysfunction
[20]. Aging also impairs AMPK activation and suppresses
insulin-stimulated glucose uptake into rat skeletal muscles,
which is held to enhance the development of metabolic
syndrome [21]. Here, we observed that phosphorylation of
both LKB1 and AMPKa were present at 6 and 12 months
of age in mouse knee cartilages, but were reduced signifi-
cantly in 24-month-old mouse knee cartilages. Our results
suggest that decreased capacity for linked LKB1 and
AMPK activation in aging chondrocytes may increase sus-
ceptibility to OA development.
Biomechanical injury can promote the development and
progression of OA [7,22]. Our translational studies of the
pharmacologic AMPK activators AICAR and highly
AMPK-selective A-769662 suggested that maintaining
AMPK activity in injured chondrocytes can promote pre-
servation of cartilage matrix integrity. Significantly, we
established and validated a new, sub-lethal biomechanical
injury condition for chondrocytes in three-dimensional
chondrocyte-alginate constructs. In this system, concur-
rent loss of phosphorylation of LKB1 and AMPKa, asso-
ciated with induction of caspase-3 activation, release of
NO and GAG, and MMP-3 expression, developed in
response to injury. Conversely, treatment of chondrocyte-
alginate constructs with AMPK pharmacologic activators
AICAR and A-769662 prevented dephosphorylation of
AMPKa and inhibited caspase-3 activation and catabolic
responses induced by biomechanical injury.
There are several core limitations to this study. First,
chondrocytes can retain their phenotype and produce
physiological cartilage matrix components when immobi-
lized in alginate, but the biomechanical properties of
three-dimensional chondrocyte-alginate constructs may
not be identical to those in articular cartilage. Future bio-
mechanical injury studies with articular cartilage explants
would be of interest. Second, the scope of analyses herein
focused on the relationship between LKB1 and AMPK
activity. However, regulation of AMPK involves phos-
phorylation by two upstream kinases in addition to
LKB1; that is, calcium calmodulin-dependent kinase
kinase beta and transforming growth factor beta-
activated kinase 1 [10,11]. Whether calcium calmodulin-
dependent kinase kinase beta and transforming growth
factor beta-activated kinase 1 regulate AMPK activation
in chondrocytes remains to be determined. Protein phos-
phatases such as protein phosphatase 2A and protein
phosphatase 2C negatively regulate AMPK activity
through dephosphorylation of AMPKa [10,11]. Unlike
the case for LKB1, however, we have not observed any
significant differences in expression of protein phospha-
tase 2Ca between human knee OA (grade III) and nor-
mal chondrocytes (grade I) (R. Liu-Bryan, unpublished
observation). Third, AMPK promotes autophagy [23,24],
which may be a protective mechanism against injury in
chondrocytes that decreases in aging cartilage [16,25].
Analysis of the relationships between LKB1 and AMPK
activity and autophagy in aging cartilage and biomechani-
cally injured chondrocytes were beyond the scope of this
study, but would be of interest.
Conclusion
Reduction in functionally linked LKB1 and AMPK acti-
vation in chondrocytes associated with aging, inflamma-
tion and biomechanical injury has the potential to
disrupt cartilage extracellular matrix homeostasis, and
thereby could contribute to OA development and pro-
gression. Pharmacologic AMPK activation is a novel
potential therapeutic approach for OA that merits
further investigation.
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